Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | GGT1 | P19440 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ARG1 | P05089 | 1/20 | 0.31 |
| ▸ | ARG2 | P78540 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4080725 | 1.00 | RNPEP (0.34) | RNPEPALDH1A1GGT1MEN1CYP1A2 | |
| SCHEMBL137240 | 0.98 | RNPEP (0.33) | RNPEPALDH1A1GGT1MEN1CYP1A2 | |
| SCHEMBL137239 | 0.98 | RNPEP (0.33) | RNPEPALDH1A1GGT1MEN1CYP1A2 | |
| SCHEMBL28286570 | 0.82 | ALDH1A1 (0.32) | RNPEPALDH1A1 | |
| SCHEMBL137238 | 0.80 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL8631296 | 0.79 | RNPEP (0.35) | RNPEPALDH1A1GGT1MEN1CYP1A2 | |
| SCHEMBL29013093 | 0.79 | RNPEP (0.35) | RNPEPALDH1A1GGT1MEN1CYP1A2 | |
| SCHEMBL162368 | 0.77 | GGT1 (0.52) | RNPEPALDH1A1GGT1MEN1CYP1A2 | |
| SCHEMBL162014 | 0.77 | GGT1 (0.52) | RNPEPALDH1A1GGT1MEN1CYP1A2 | |
| SCHEMBL243496 | 0.77 | GGT1 (0.52) | RNPEPALDH1A1GGT1MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109942466-B | Method for preparing alpha-hydroxy methionine analogue from sugar | 托普索公司 | 2021-08-27 | — | — | CN | claimed |
| CN-107549803-B | Effervescent tablet containing alpha-ketoacid and preparation method thereof | 精晶药业股份有限公司 | 2021-06-01 | — | — | CN | claimed |
| CN-106457230-B | Crystalline microporous material mediated conversion of C1-3 oxygenates to C4-oxygenates | 托普索公司 | 2020-12-11 | — | — | CN | claimed |
| CN-109942466-A | The method that Alpha-hydroxy methionine analog is prepared by sugar | 托普索公司 | 2019-06-28 | — | — | CN | claimed |
| US-10280136-B2 | Process for preparing esters of α-hydroxy methionine from sugars | HALDOR TOPSOE A/S (DK) | 2019-05-07 | — | — | US | claimed |
| CN-109414601-A | Skin care method | 博姿有限公司 | 2019-03-01 | — | — | CN | claimed |
| CN-107001253-A | Method for preparing esters of lactic acid esters and 2-hydroxy-3-butenoic acid esters or alpha-hydroxymethionine analogues from sugars | 托普索公司 | 2017-08-01 | — | — | CN | claimed |
| CN-106457230-A | Crystalline microporous material mediated conversion of C1-3 oxygenate compounds to C4- oxygenate compounds | 托普索公司 | 2017-02-22 | — | — | CN | claimed |
| EP-4547648-A1 | METHOD FOR THE PRODUCTION OF ALPHA HYDROXY-ALKYLTHIO CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | AMINO GmbH (DE) | 2025-05-07 | — | — | EP | disclosed |
| WO-2024002633-A1 | METHOD FOR THE PRODUCTION OF ALPHA HYDROXY-ALKYLTHIO CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | AMINO GMBH (DE) | 2024-01-04 | — | — | WO | disclosed |
| EP-4299560-A1 | METHOD FOR THE PRODUCTION OF ALPHA HYDROXY-ALKYLTHIO CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | AMINO GmbH (DE) | 2024-01-03 | — | — | EP | disclosed |
| US-11642314-B2 | Mixtures of branched chain keto acids (BCKA) and method for the production of such mixtures | EVONIK OPERATIONS GMBH (DE) | 2023-05-09 | — | — | US | disclosed |
| US-20210290544-A1 | MIXTURES OF BRANCHED CHAIN KETO ACIDS (BCKA) AND METHOD FOR THE PRODUCTION OF SUCH MIXTURES | EVONIK OPERATIONS GMBH (DE) | 2021-09-23 | — | — | US | disclosed |
| CN-109942466-B | Method for preparing alpha-hydroxy methionine analogue from sugar | 托普索公司 | 2021-08-27 | — | — | CN | disclosed |
| US-20070243581-A1 | Process for Producing Dipeptides | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-10-18 | — | — | US | disclosed |
| US-20070218525-A1 | Process for Producing Dipeptides | KYOWA HAKKO KOGYO CO., LTD. | 2007-09-20 | — | — | US | disclosed |
| US-20070128687-A1 | Comprises enzyme source and diketopiperazine, wherein aspartic acid and phenylalanine are condensed with each other | KYOWA HAKKO BIO CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| EP-1760152-A1 | PROCESS FOR PRODUCING DIPEPTIDE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-03-07 | — | — | EP | disclosed |
| EP-1736540-A1 | PROCESS FOR PRODUCING DIPEPTIDES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-12-27 | — | — | EP | disclosed |
| EP-1698703-A1 | PROCESS FOR PRODUCING DIPEPTIDE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11642314-B2 | Mixtures of branched chain keto acids (BCKA) and method for the production of such mixtures | BCKDK, BCAT2, BCAT1 | RNPEP 1496/4885ALDH1A1 1745/4885GGT1 3860/4885 |
| US-20210290544-A1 | MIXTURES OF BRANCHED CHAIN KETO ACIDS (BCKA) AND METHOD FOR THE PRODUCTION OF SUCH MIXTURES | BCKDK, BCAT2, BCAT1 | RNPEP 1484/4885ALDH1A1 1764/4885GGT1 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.